Clinical trial
A Phase 1-2 Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
NCT05155215 is registered in ClinicalTrials.gov with Beijing Immunochina Medical Science & Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1-2 Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
- Lead sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- December 31, 2021
- Completion date
- February 28, 2023
- Enrollment
- 68 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.